Please login to the form below

Not currently logged in

Teva launches study bursaries

Teva UK has launched a new study bursary scheme to tackle what it calls a 'demographic time-bomb' facing British-based pharmacy.
Teva UK has launched a new study bursary scheme to tackle what it calls a 'demographic time-bomb' facing British-based pharmacy. Pharmacists are getting older and selling-up creating a pressing need for new people to be recruited and trained, said Philippa Ward, communications and PR officer at the company.

Any home UK student already taking or offered a place on any full-time undergraduate course at a British academic institution can apply for the bursaries which will be awarded to potential pharmacy graduates who would otherwise struggle to cope financially. Teva already has initiatives in operation to support pharmacists in the changing healthcare environment but is looking to give its backing to future sector professionals.

Lynda Wilebore, Teva's HR director, said: "We are delighted to be able to introduce the student bursary scheme, which we hope will make an important contribution to the lives of under-privileged students in the UK."

"We are totally committed to pharmacy in the UK. This means we're not only interested in supporting the pharmacists of today, but also in ensuring the pharmacists of tomorrow get the best possible start," she concluded.

Wilebore explained that it is important to the interests of Teva, a UK generics manufacturer, that it has in place a community support programme that is relevant to its business.

Preference for the bursaries will be given to A-level students who are in receipt of education maintenance allowance or carers' allowance. The company will award 10 bursaries per year. Each one will be worth £500 per academic year of study and the deadline for the current round of applications is September 1, 2008.

14th May 2008


Featured jobs

Subscribe to our email news alerts


Add my company

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...